Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO
Oslo, Norway, 28 April 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that two ONCOS-102 abstracts have been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago 3-7 June 2022.The abstracts will be released on the ASCO website 26 May 17:00 CEST . The posters are scheduled for presentation during the ASCO congress 3 – 7 June 2022.